Editorial · 22 Jul 2022
Conference abstractPublished 21 Nov 2016
Oncolytic virotherapy with Rigvir
Riga Eastern Clinical University Hospital-Riga StradiÃ?¡ University, Latvia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of Problem: Melanoma is one of the fastest growing cancers and has the highest mortality-rate of skin cancers. The oncolytic property of viruses has been observed for over a century and is presently intensively studied. RigvirÃ?® is the first registered oncolytic virus and the only one approved that has not been genetically modified. It is an ECHO-7 virus registered for melanoma therapy. The present retrospective study was made to determine the effectiveness of RigvirÃ?® in sub-stage IB, IIA, IIB and IIC melanoma patients on overall survival. Methodology & Theoretical Orientation: Caucasian patients (N=79) who had surgical excision of the primary melanoma tumor and histologically verified diagnosis were included in the study. Circulating levels of clinical chemistry parameters were recorded. Survival was analyzed by multivariate Cox regression. Current guidelines for melanoma advise no treatment for patients who are classified into sub stages IB and IIA. Patients in sub-stages IIB and IIC were given three options: Participation in a clinical trial, observation, and interferon. Thus, 52 study participants received RigvirÃ?® and 27 were observed according to guidelines. Due to the low number, the patients treated with interferon are excluded. The study was approved by the respective ethics committee. Findings: RigvirÃ?® significantly prolonged survival in sub-stage IB-IIC melanoma patients following surgery compared to patients who were under observation. The hazard ratio (HR) for patients under observation vs. treated with RigvirÃ?® is statistically significantly different: HR 6.27 for all, 4.39 for sub-stage IIA-IIB-IIC and 6.57 for sub-stage IIB-IIC patients. Safety assessment of adverse events according to NCI-CTCAE did not show any value above grade 2 in RigvirÃ?® treated patients. Conclusions & Significance: These results show that the patients treated with RigvirÃ?® had 4.39-6.57 times lower mortality than those under observation. In this study, there was no untoward side effect or discontinuation of RigvirÃ?® treatment. Recent Publications DoniÃ?Â?a S, StrÃ?Â?le I, Proboka G, AuziÃ?Â?Ã?¡ J, Alberts P, Jonsson B, Venskus D and Muceniece A (2015) Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumor in a retrospective study. Melanoma Research 25:421âÂ?Â?426.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 6 Jun 2018
Oncolytic Virotherapy for Clear Cell Ovarian Carcinoma: a potential treatment strategy
Conference abstract · 21 Jul 2016
Modulating the antioxidant defenses to potentiate oncolytic virotherapy in prostate cancer
Brief report · 28 Oct 2021
A Report on Oncolytic Virotherapy
Conference abstract · 29 Mar 2018
The foe that extends a helping hand: Oncolytic virotherapy, present and future prospective
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Simona Donina”

